

LITERATURA

- Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. *Circ Res.* 2020;127(1):4-20. doi:10.1161/CIRCRESAHA.120.316340
- Williams BA, Chamberlain AM, Blankenship JC, Hylek EM, Voyce S. Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018. *JAMA Netw Open.* 2020;3(8):e2014874. doi:10.1001/jamanetworkopen.2020.14874
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. *Arch Intern Med.* 1987;147(9):1561-1564.
- Di Carlo A. Human and economic burden of stroke. *Age Ageing.* 2009;38(1):4-5. doi:10.1093/ageing/afn282
- Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med.* 1999;131(7):492-501. doi:10.7326/0003-4819-131-7-199910050-00003
- Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. *Thromb Haemost.* 2011;106(5):968-977. doi:10.1160/TH11-05-0353
- Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med.* 2011;365(21):2002-2012. doi:10.1056/NEJMsa1103053
- Witt DM, Delate T, Garcia DA et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. *Arch Intern Med.* 2012;172(19):1484-1491. doi:10.1001/archinternmed.2012.4261
- Alberts MJ, Bhatt DL, Smith SC et al. Risk factors and outcomes for patients with vascular disease and serious bleeding events. *Heart Br Card Soc.* 2011;97(18):1507-1512. doi:10.1136/hrt.2010.221788
- Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
- Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
- Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907
- Laliberté F, Cloutier M, Crivera C et al. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users. *Clin Ther.* 2015;37(3):554-562. doi:10.1016/j.clinthera.2015.02.001
- Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. *Drug Metab Dispos Biol Fate Chem.* 2009;37(1):74-81. doi:10.1124/dmd.108.023143
- Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. *J Med Econ.* 2015;18(6):399-409. doi:10.3111/13696998.2015.1007210
- Lip GYH, Kongnakorn T, Phatak H et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. *Clin Ther.* 2014;36(2):192-210. e20. doi:10.1016/j.clinthera.2013.12.011
- Lanitis T, Kongnakorn T, Jacobson L, De Geer A. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. *Thromb Res.* 2014;134(2):278-287. doi:10.1016/j.thromres.2014.05.027
- Costa J, Fiorentino F, Caldeira D et al. Custo-efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal. *Rev Port Cardiol.* 2015;34(12):723-737. doi:10.1016/j.repc.2015.07.004
- Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. *J Med Econ.* 2014;17(11):771-781. doi:10.3111/13696998.2014.953682
- Ruiz MA, González-Porras JR, Aranguren JL et al. Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®. *Qual Life Res Int J Qual Life Asp Treat Care Rehabil.* 2017;26(3):767-778. doi:10.1007/s11136-016-1474-4
- Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a „real-world“ population with atrial fibrillation receiving anticoagulant therapy. *Chest.* 2013;143(1):179-184. doi:10.1378/chest.12-0608
- Lip GYH, Nieuwlaet R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest.* 2010;137(2):263-272. doi:10.1378/chest.09-1584
- Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. *Stroke.* 2018;49(1):98-106. doi:10.1161/STROKEAHA.117.018395

SLEDUJTE NÁS NA FACEBOOKU

AKTUÁLNÍ INFORMACE
ze vzdělávání lékařů a lékárníků

- f odemykáme články** k aktuálním tématům
- f upozorňujeme na** blížící se vzdělávací akce
- f informujeme o** nových on-line kurzech s registrací zdarma
- f připravujeme soutěže** o vstupenky na kongresy a předplatné časopisů ...

<https://www.facebook.com/SolenMedicalEducation/>

